Loading
A phase 3 trial of Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide and Carboplatin in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer. ClinicalTrials.gov record last updated 2026-07-13: active not recruiting. Enrollment is actual at 1902 participants. Primary completion is estimated at 2028-11-20. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib. Registered primary measures: Event-free survival (EFS) in the experimental vs control arms.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epirubicin, TROP2, Early triple-negative breast cancer, Doxorubicin and the tag pipeline.
Shares Epirubicin, Daiichi Sankyo, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Datopotamab deruxtecan, TROP2, Durvalumab, AstraZeneca and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Pembrolizumab and the tag pipeline.
Shares TROP2, Early triple-negative breast cancer, Triple-negative breast cancer (TNBC), Pembrolizumab and the tag pipeline.
Shares Datopotamab deruxtecan, Daiichi Sankyo, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Datopotamab deruxtecan, Durvalumab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), AstraZeneca and the tag pipeline.
Shares Olaparib, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/